Evaluation of MMP‑2, MMP‑9, TIMP‑1, TIMP‑2, NGAL and MMP‑9/NGAL complex in urine and sera from patients with bladder cancer

Oncology Letters

Volumn 10, Issue 4, 2015, Pages 2527-2532

  Ricci, Serena ^a   Bruzzese, Dario ^a   Di Carlo, Angelina ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bladder carcinoma; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Neutrophil gelatinase associated lipocalin; Sera; Tissue inhibitor of metalloproteinase 1; Tissue inhibitor of metalloproteinase 2; Urine

Indexed keywords

GELATINASE A; GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; COMPLEX FORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

EID: 84940043098     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3558     Document Type: Article

References (27)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010.
2. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A and Abnet CC: Association between smoking and risk of bladder cancer among men and women. JAMA 306: 737-745, 2011.
3. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S and Lotan Y: Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63: 234-241, 2013.
4. Wu XR: Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 5: 713-725, 2005.
5. Montie JE, Bahnson RR, Cohen SM, Drucker B, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, et al; National Comprehensive Cancer Network: Bladder cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 1: 19-34, 2005.
6. Carlo A, Terracciano D, Mariano A, Oliva A, D'Armiento M and Macchia V: Role of cytokeratins, nuclear matrix proteins, Lewis antigen and epidermal growth factor receptor in human bladder tumors. Int J Oncol 23: 757-762, 2003.
7. Vrooman OP and Witjes JA: Urinary marker in bladder cancer. Eur Urol 53: 909-916, 2008.
8. Van Tilborg AA, Bangma CH and Zwarthoff EC: Bladder cancer biomarkers and their role in surveillance and screening. Int J Urol 16: 23-30, 2009.
9. Shariat SF, Passoni N, Bagrodia A, Rachakonda V, Xylinas E, Robinson B, Kapur P, Sagalowsky AI and Lotan Y: Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. BJU Int 113: 70-76, 2014.
10. Brinckerhoff CE and Matrisian LM: Matrix metalloproteinases: A tail of a frog that became a prince. Nat Rev Mol Cell Biol 3: 207-214, 2002.
11. Di Carlo A, Mariano A, Terracciano D, Mazzarella C, Galzerano S, Cicalese M, Cecere C and Macchia V: Gelatinolytic activities (matrix metalloproteinase-2 and -9) and soluble extracellular domain of Her-2/neu in pleural effusions. Oncol Rep 18: 425-431, 2007.
12. Nagase H, Visse R and Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69: 562-573, 2006.
13. Di Carlo A, Terracciano D, Mariano A and Macchia V: Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors. Oncol Rep 15: 1321-1326, 2006.
14. Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, Zurakowski D and Moses MA: Tumor-specific urinary matrix metalloproteinase fingerprinting: Identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 14: 6610-6617, 2008.
15. Chakrabotory S, Kaur S, Guha S and Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochem Biophys Acta 1826: 129-169, 2012.
16. Di Carlo A: Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors. Oncol Lett 5: 1677-1681, 2013.
17. Volpe V, Raia Z, Sanguigno L, Somma D, Mastrovito P, Moscato F, Mellone S, Leonardi A and Pacifico F: NGAL controls the metastatic potential of anaplastic thyroid carcinoma cells. J Endocrinol Metab 98: 228-235, 2013.
18. Bouchet S and Bauvois B: Neutrophil gelatinase-associated lipocalin (NGAL), pro-matrix metalloproteinase-9 (pro-MMP-9) and their complex Pro-MMP-9/NGAL in leukemias. Cancers (Basel) 6: 796-812, 2014.
19. Hoboken NJ: Urological tumours. In: TNM Classification of Malignant Tumors. Sobin LH, Gospodariwicz M and Wittekind C (eds). 7th edition. Wiley-Blackwell, London, pp262-265, 2009.
20. Shariat SF, Palapattu GS, Karakiewicz PI, Roger CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI and Lotan Y: Discrepancy between clinical and pathological stage: Impact on prognosis after radical cystectomy. Eur Urol 51: 137-149, 2007.
21. Szarvas T, vom Dorp F, Ergün S and Rübben H: Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat Rev Urol 8: 241-254, 2011.
22. Gomez DE, Alonso DF, Yoshiji H and Thorgeirsson UP: Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 74: 111-122, 1997.
23. Hayakawa T: Tissue inhibitors of metalloproteinases and their cell growth-promoting activity. Cell Struct Funct 19: 109-114, 1994.
24. Miyata Y, Kanda S, Nomata K, Hayashida Y and Kanetake H: Expression of metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: Correlation with tumor stage and survival. Urology 63: 602-608, 2004.
25. Durkan GC, Nutt JE, Rajjayabun PH, Neal DE, Lunec J and Mellon JK: Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clinical Cancer Res 7: 3450-3456, 2001.
26. Monier F, Mollier S, Guillot M, Rambeaud JJ, Morel F and Zaoui P: Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas. Eur Urol 42: 356-363, 2002.
27. Candido S, Maestro R, Polesel J, Catania A, Maira F, Signorelli SS, McCubrey JA and Libra M: Role of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget 5: 1576-1594, 2014.